한글목차

세계의 바이러스 검사 키트 시장 규모는 2024년에 165억 7,000만 달러로 평가되었고, 예측 기간 중의 CAGR은 5.29%를 나타내, 2030년에는 225억 8,000만 달러에 달할 것으로 예상됩니다.

바이러스 검사 키트는 DFA, 응집 시험, PCR, 고상 시험 등 다양한 검사 방법으로 감염된 사람의 항체를 검출하는 데 사용되는 진단 도구입니다. 바이러스는 신체의 면역 방어에 중요한 역할을하는 림프구에 점차 영향을 미칩니다. 핵산을 시각적으로 확인하기 위한 효소-보조 나노복합체와 같은 첨단 기술 플랫폼은 광범위한 질병을 검출하도록 설계될 수 있습니다. 이 키트는 신흥 감염과 유행률이 높은 감염을 제어하는 데 도움이 됩니다. 이 키트는 신속 항원 검사, 혈청 검사, 바이러스 항체를 검출하는 분자진단 등 바이러스학 연구소에서 일반적으로 사용되는 기술을 기반으로 합니다. 세계보건기구(WHO)의 데이터에 따르면 2022년 2월 기준 세계에서 4억 2,200만명 이상의 확정 증례와 580만명 이상의 사망 예가 보고되었습니다. 이 COVID-19 감염의 급증으로 COVID-19 검출 키트 수요가 세계적으로 크게 증가하고 있습니다.

시장 성장 촉진요인

감염증 이환율 증가

주요 시장 과제

LMIC(저·중소득국) 전체에서의 인식 부족

주요 시장 동향

성장 기회를 제공하는 신흥 경제국

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 바이러스 검사 키트 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율·예측
  • 검사 유형별(DFA 검사, 측면 흐름 검사, RT-PCR, 응집 분석, 고상 분석, 기타)
  • 용도별(인플루엔자, 간염, HIV, 홍역/풍진, 로타바이러스, 기타)
  • 최종 사용자별(병원 및 진료소, 진단센터 및 연구소, 학술 및 연구 기관, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 바이러스 검사 키트 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 바이러스 검사 키트 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 바이러스 검사 키트 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 바이러스 검사 키트 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 바이러스 검사 키트 시장 전망

• 시장 규모와 예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 합병과 인수
• 제품 출시

제13장 세계의 바이러스 검사 키트 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Qiagen NV
• Abbott Laboratories Inc
• Thermo Fisher Scientific Inc
• Becton, Dickinson and Company
• BioMerieux SA
• Quidel Corporation
• Rapikit
• Zoetis Inc
• Luminex Corporation
• F. Hoffmann-La Roche Ltd

제16장 전략적 제안

제17장 기업 소개와 면책사항

영문목차

Global Virus Testing Kits Market has valued at USD 16.57 Billion in 2024 and is expected to reach USD 22.58 Billion by 2030 with a CAGR of 5.29% during the forecast period. The virus test kit is a diagnostic tool used to detect antibodies in infected individuals through various testing methods, including DFA, agglutinating testing, PCR, and solid-stage testing. The virus progressively affects lymphocytes, which play a vital role in the body's immune defense. Advanced technology platforms, such as enzyme-assisted nano complexes for visual identification of nucleic acids, can be designed to detect a wide range of diseases. These kits are instrumental in controlling emerging infectious diseases and high-prevalence infections. They are based on techniques commonly employed in virology laboratories for rapid antigen testing, serology, and molecular diagnostics to detect virus antibodies. According to the World Health Organization (WHO) data, as of February 2022, over 422 million confirmed cases and over 5.8 million deaths have been reported globally. This surge in COVID-19 infections has led to a significant increase in the demand for COVID-19 detection kits globally.

Key Market Drivers

Growing Prevalence of Infectious Diseases

The increasing global burden of rare diseases necessitates accurate diagnosis and effective treatment strategies for various chronic conditions. Developing countries such as China, India, Japan, Brazil, and other Southeast Asian nations have witnessed improved diagnosis rates due to heightened awareness of terminal illness symptoms. However, even with technologically advanced diagnostic equipment, a small margin of human error still hinders the process, resulting in a significant number of patients remaining undiagnosed at an early stage and complicating treatment. Influenza epidemics and pandemics have a profound impact on both individuals and populations. For instance, the National Institutes of Health serosurvey includes investigating blood samples of over 10,000 U.S. adults with no confirmed history of coronavirus infection to detect anti-SARS-CoV-2 protein IgM and IgG antibodies. It also includes additional tests to evaluate the immune responses of volunteers to the virus. The burden of influenza varies depending on age and underlying health conditions, with high-risk patients, such as the elderly and those with pre-existing medical conditions, experiencing more frequent hospitalizations and care. As patient populations continue to grow, there is an increasing need to assess the burden of influenza, particularly due to escalating medical costs. However, accurately estimating disease prevalence can be challenging, as influenza is often mistaken for other viral illnesses, leading to under-reporting. In addition to direct costs associated with medical care, such as absenteeism and loss of work efficiency, indirect costs of influenza are substantial. Cost estimates from France, the United States, and Germany have shown that indirect costs can be five to ten times higher than direct costs. Thus, understanding the true burden of influenza is crucial for effective resource allocation and mitigation strategies.

Key Market Challenges

Lack of Awareness Across LMIC (Low- and Middle-Income Countries) Economies

The field of diagnosis distinguishes itself from other sectors of the pharmaceutical industry due to a shorter life cycle for virus diagnostic products and variations in regulatory approval methods. The diagnostic market is experiencing growth, particularly in emerging countries, driven by government initiatives to improve healthcare facilities and an increasing patient population. However, limited accessibility to diagnostic tests in emerging economies remains a challenge compared to developed economies. LMIC economies often have limited access to reliable information due to challenges such as low literacy rates, lack of internet connectivity, and limited healthcare infrastructure. This results in a lack of awareness about the importance of virus testing and the availability of testing kits. Many LMICs face challenges in providing adequate health education to their populations. As a result, individuals may not fully understand the importance of timely testing for infectious diseases.

Lack of healthcare infrastructure, including laboratories and testing facilities, can limit the availability of testing services and hinder awareness campaigns. High healthcare costs and limited access to health insurance can deter individuals from seeking testing, especially when they are not fully aware of its importance. Individuals in LMICs may have competing priorities for their limited resources, such as food, housing, and education. This can lead to healthcare taking a lower priority, including the decision to undergo testing.

Key Market Trends

Emerging Economies to Offer Lucrative Growth Opportunities

Emerging economies like India, Brazil, and China present lucrative opportunities for the private health sector. Multinational companies have established their presence in these countries through partnerships or acquisitions of local diagnostic firms. In developing nations such as India, China, and Brazil, where improving living standards and an aging population drive the demand for chronic disease diagnosis and management, the disease burden is undergoing a transformation. Emerging economies offer immense potential for growth in the private health sector. The rising middle class, increased urbanization, and growing disposable incomes are driving higher demand for quality healthcare services, including diagnostics, treatments, and management of chronic diseases. Many multinational healthcare companies recognize the opportunities in these markets and are establishing their presence through strategic partnerships, collaborations, acquisitions, or investments in local diagnostic firms. This allows them to leverage local expertise and infrastructure while expanding their global footprint. Collaborating with or acquiring local diagnostic firms provides multinational companies with an understanding of local market dynamics, regulatory frameworks, and patient needs. This enables them to tailor their offerings effectively and navigate regulatory challenges. These factors collectively contribute to the promising growth prospects for manufacturers of virus diagnostic kits.

Key Market Players

• Qiagen N.V.
• Abbott Laboratories Inc
• Thermo Fisher Scientific Inc
• Becton, Dickinson and Company
• BioMerieux SA
• Quidel Corporation
• Rapikit
• Zoetis Inc
• Luminex Corporation
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Virus Testing Kits Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Virus Testing Kits Market, By Test Type:

• DFA Tests
• Lateral Flow Tests
• RT-PCR
• Agglutination Assays
• Solid-Phase Assays
• Others

Virus Testing Kits Market, By Application:

• Influenza
• Hepatitis
• HIV
• Measles/Rubella
• Rotavirus
• Others

Virus Testing Kits Market, By End User:

• Hospitals & Clinics
• Diagnostic Centres & Laboratories
• Academic & Research Institutions
• Others

Virus Testing Kits Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Available Customizations:

Global Virus Testing Kits market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Virus Testing Kits Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (DFA Tests, Lateral Flow Tests, RT-PCR, Agglutination Assays, Solid-Phase Assays, Others)
  • 5.2.2. By Application (Influenza, Hepatitis, HIV, Measles/Rubella, Rotavirus, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centres & Laboratories, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Virus Testing Kits Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Virus Testing Kits Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Virus Testing Kits Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Virus Testing Kits Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Virus Testing Kits Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Virus Testing Kits Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Virus Testing Kits Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Virus Testing Kits Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Virus Testing Kits Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Virus Testing Kits Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Virus Testing Kits Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Virus Testing Kits Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Virus Testing Kits Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Virus Testing Kits Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Virus Testing Kits Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Virus Testing Kits Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Virus Testing Kits Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Virus Testing Kits Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Virus Testing Kits Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Virus Testing Kits Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Virus Testing Kits Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Virus Testing Kits Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Virus Testing Kits Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Virus Testing Kits Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Virus Testing Kits Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Qiagen N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Abbott Laboratories Inc
• 15.3. Thermo Fisher Scientific Inc
• 15.4. Becton, Dickinson and Company
• 15.5. BioMerieux SA
• 15.6. Quidel Corporation
• 15.7. Rapikit
• 15.8. Zoetis Inc
• 15.9. Luminex Corporation
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer